Checkpoint molecules coordinately restrain hyperactivated effector T cells in the tumor microenvironment
Published 2020 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Checkpoint molecules coordinately restrain hyperactivated effector T cells in the tumor microenvironment
Authors
Keywords
-
Journal
OncoImmunology
Volume 9, Issue 1, Pages 1708064
Publisher
Informa UK Limited
Online
2020-01-31
DOI
10.1080/2162402x.2019.1708064
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- TIM-3 Regulates CD103 + Dendritic Cell Function and Response to Chemotherapy in Breast Cancer
- (2018) Álvaro de Mingo Pulido et al. CANCER CELL
- Novel effector phenotype of Tim-3+ regulatory T cells leads to enhanced suppressive function in head and neck cancer patients
- (2018) Zhuqing Liu et al. CLINICAL CANCER RESEARCH
- Immunophenotyping of Newly Diagnosed and Recurrent Glioblastoma Defines Distinct Immune Exhaustion Profiles in Peripheral and Tumor-infiltrating Lymphocytes
- (2018) Malte Mohme et al. CLINICAL CANCER RESEARCH
- Increased Tim-3+ T cells in PBMCs during nivolumab therapy correlate with responses and prognosis of advanced esophageal squamous cell carcinoma patients
- (2018) Ryo Kato et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Induction and transcriptional regulation of the co-inhibitory gene module in T cells
- (2018) Norio Chihara et al. NATURE
- Tim-3 Expression on Tumor-Infiltrating PD-1 + CD8 + T Cells Correlates with Poor Clinical Outcome in Renal Cell Carcinoma
- (2016) Clémence Granier et al. CANCER RESEARCH
- PD-1 Blockade Boosts Radiofrequency Ablation-Elicited Adaptive Immune Responses against Tumor
- (2016) L. Shi et al. CLINICAL CANCER RESEARCH
- The Tumor Microenvironment Represses T Cell Mitochondrial Biogenesis to Drive Intratumoral T Cell Metabolic Insufficiency and Dysfunction
- (2016) Nicole E. Scharping et al. IMMUNITY
- Combinatorial approach to cancer immunotherapy: strength in numbers
- (2016) Anna E. Vilgelm et al. JOURNAL OF LEUKOCYTE BIOLOGY
- Interleukin-33 in tumorigenesis, tumor immune evasion, and cancer immunotherapy
- (2016) Binfeng Lu et al. JOURNAL OF MOLECULAR MEDICINE-JMM
- Adaptive resistance to therapeutic PD-1 blockade is associated with upregulation of alternative immune checkpoints
- (2016) Shohei Koyama et al. Nature Communications
- TIM-3 Regulates Distinct Functions in Macrophages
- (2016) Ranferi Ocaña-Guzman et al. Frontiers in Immunology
- Tumor-infiltrating Tim-3+ T cells proliferate avidly except when PD-1 is co-expressed: Evidence for intracellular cross talk
- (2016) Jing Li et al. OncoImmunology
- Dissecting the Tumor Myeloid Compartment Reveals Rare Activating Antigen-Presenting Cells Critical for T Cell Immunity
- (2014) Miranda L. Broz et al. CANCER CELL
- Galectin-9 Increases Tim-3+ Dendritic Cells and CD8+ T Cells and Enhances Antitumor Immunity via Galectin-9-Tim-3 Interactions
- (2014) K. Nagahara et al. JOURNAL OF IMMUNOLOGY
- Enhanced Virus-Specific CD8+ T Cell Responses by Listeria monocytogenes-Infected Dendritic Cells in the Context of Tim-3 Blockade
- (2014) Cheng J. Ma et al. PLoS One
- A Disintegrin and Metalloprotease (ADAM) 10 and ADAM17 Are Major Sheddases of T Cell Immunoglobulin and Mucin Domain 3 (Tim-3)
- (2013) Katja Möller-Hackbarth et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- The immunosuppressive tumour network: myeloid-derived suppressor cells, regulatory T cells and natural killer T cells
- (2012) Dennis Lindau et al. IMMUNOLOGY
- Tumor-infiltrating DCs suppress nucleic acid–mediated innate immune responses through interactions between the receptor TIM-3 and the alarmin HMGB1
- (2012) Shigeki Chiba et al. NATURE IMMUNOLOGY
- Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer
- (2012) Suzanne L. Topalian et al. NEW ENGLAND JOURNAL OF MEDICINE
- TIM-3 Expression Characterizes Regulatory T Cells in Tumor Tissues and Is Associated with Lung Cancer Progression
- (2012) Xin Gao et al. PLoS One
- Anti-TIM3 Antibody Promotes T Cell IFN- -Mediated Antitumor Immunity and Suppresses Established Tumors
- (2011) S. F. Ngiow et al. CANCER RESEARCH
- Immune Inhibitory Molecules LAG-3 and PD-1 Synergistically Regulate T-cell Function to Promote Tumoral Immune Escape
- (2011) S.-R. Woo et al. CANCER RESEARCH
- Tim-3 regulates pro- and anti-inflammatory cytokine expression in human CD14+ monocytes
- (2011) Ying Zhang et al. JOURNAL OF LEUKOCYTE BIOLOGY
- Upregulation of Tim-3 and PD-1 expression is associated with tumor antigen–specific CD8+T cell dysfunction in melanoma patients
- (2010) Julien Fourcade et al. JOURNAL OF EXPERIMENTAL MEDICINE
- Targeting Tim-3 and PD-1 pathways to reverse T cell exhaustion and restore anti-tumor immunity
- (2010) Kaori Sakuishi et al. JOURNAL OF EXPERIMENTAL MEDICINE
- Tumor-infiltrating NY-ESO-1–specific CD8+T cells are negatively regulated by LAG-3 and PD-1 in human ovarian cancer
- (2010) Junko Matsuzaki et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Coregulation of CD8+ T cell exhaustion by multiple inhibitory receptors during chronic viral infection
- (2008) Shawn D Blackburn et al. NATURE IMMUNOLOGY
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started